Background
==========

Osteoporosis, a chronic condition characterized by low bone mass, microarchitectural deterioration of bone and increased risk of fracture, is a significant public health concern. It affects over 200 million people worldwide \[[@B1]\], an estimated 10 million people in the US \[[@B2]\], 4 million people in the UK \[[@B3]\] and 1.4 million people in Canada \[[@B2],[@B4]\]. Fragility fractures are the clinical consequence of osteoporosis. While vertebral fractures can cause back pain, loss of height and disability \[[@B5]-[@B7]\], hip fractures have a more significant impact on quality of life leading to loss of function, and admission to long-term care \[[@B8]-[@B12]\]. It is estimated that 1 in 5 people who suffer a hip fracture will die during the first year and less than one third gain their pre-fracture level of function \[[@B2]\]. Moreover, the economic impact of this condition is considerable, with the total acute care cost of osteoporosis estimated to be over \$1.3 billion per year in Canada \[[@B12]\], \$20 billion in the US \[[@B13]\] and over €30 billion in Europe \[[@B14],[@B15]\]. Given that the proportion of people aged 65 and older is increasing, this will likely lead to an even more significant burden of disease \[[@B4],[@B15]\].

A substantial body of evidence supports the use of various interventions for the detection and treatment of osteoporosis in high risk patients, and the prevention of related fractures including therapy with calcium, vitamin D, and drugs that decrease bone resorption or increase bone formation \[[@B16]\]. For example, bisphosphonates reduce the risk of future osteoporosis-related fracture by 40 to 60% with fracture reduction apparent within a year of starting treatment \[[@B16]\].

Despite the incorporation of this evidence from randomized trials into clinical practice guidelines, these interventions are considerably underutilized \[[@B17]-[@B23]\]. A systematic review found that the proportion of individuals with a fragility fracture who received a diagnostic test for osteoporosis or a diagnosis from a physician ranged from 1.7% to 50% \[[@B18]\]. Furthermore, rates of osteoporosis treatment among elderly patients with a fracture of the wrist, hip or vertebrae are less than 10 to 20% in the year following fracture \[[@B18]\].

These care gaps highlight the finding that additional effort is needed to ensure that appropriate knowledge translation is achieved to optimize management of osteoporosis in patients at risk of fragility fractures. This study was designed to help fill this knowledge to practice gap. The primary objective of this study was to determine if a multicomponent, community-based strategy could optimize the evidence-based management of people at risk for osteoporosis-related fractures.

Methods
=======

Between March 2003 and January 2006, we conducted a randomized trial of a multifaceted community based intervention to optimize care of patients at risk for osteoporosis-related fractures. The complete study protocol has been published \[[@B24]\].

Setting and Study Population
----------------------------

This was a population-based study completed in the Algoma District of Ontario, Canada, a geographically vast area with Sault Ste Marie (population 78 000) as its main city. The study represented a partnership among consumers, providers and other stakeholders interested in reducing the evidence to practice gap. It was conducted by the Group Health Centre (GHC), a not-for-profit health service community centre, in partnership with Sault Area Hospital (SAH), a facility with 250 active beds.

Patients were eligible for inclusion in the study if they were community-dwelling, aged 55 years or older, able to give informed consent, and were identified to be at risk for future fracture according to one of the following criteria:

1\. attended the hospital Fracture Clinic for a non-pathological fracture of the vertebrae, hip or wrist or had a BMD in the past year with a T-score of ≤-2.0

2\. attended the hospital Emergency Department with a fall and found to be at high risk for falls as defined by a Timed Up and Go \[[@B25]\] result of greater than 14 seconds; or,

3\. were self-referred or referred by a health care provider because of perceived high risk of fracture and identified as a high risk for falls defined by a Timed Up and Go result of greater than 14 seconds.

Patients already receiving appropriate pharmacological therapy for osteoporosis as outlined in the Osteoporosis Canada guidelines \[[@B16]\] were excluded from the study.

Intervention
------------

The intervention was multifaceted and consisted of providing evidence-based management strategies for osteoporosis to both the patients and their primary care providers. Following randomization, a bone mineral density (BMD) test was facilitated for participants during the intervention if it had not been done within the past year, and the results were sent to the primary care physician along with relevant prescribing information based on the Osteoporosis Canada guidelines \[[@B16]\]. A complete list of the patient\'s medications was compiled from two sources and provided to physicians: (1) the patient\'s pharmacy records; and (2) home visits conducted by the study nurses. Medications associated with increased risk of fracture were identified, and physicians were asked to assess this list of flagged medications (Appendix). The nurse assessed participants allocated to the intervention group in their home and completed the Berg Balance Scale \[[@B26]\], the InterRAI Screener \[[@B27],[@B28]\], a medication review and an assessment for orthostatic hypotension

Patients received personalized counseling from the research nurse about osteoporosis, including a written summary of the proposed management plan. They also received educational materials on calcium and vitamin D, risk factors for osteoporosis, and their BMD results. For those few individuals without a primary care physician, the same materials were provided but patients were encouraged to visit a walk-in clinic or the emergency department.

Allocation and Blinding
-----------------------

Eligible patients were randomized using a computer generated randomization scheme under supervision of the study biostatistician, into an immediate intervention protocol (IP) group or to usual care. 6 months after randomization participants in the usual care group received the intervention and were thus described as the delayed intervention protocol (DP) group. Patients, treating physicians and outcomes assessors could not be blinded to the fact that patients were participating in an osteoporosis improvement study. All patients were followed-up at 6 and 12 months after the completion of the initial assessment.

Outcomes and Data Collection
----------------------------

The primary outcome under investigation was appropriate osteoporosis management based on the 2002 clinical practice guidelines for osteoporosis in Canada \[[@B16]\]. This was the most current evidence-based guideline available for use at the time of study onset and was generally consistent with current US and UK guidelines. Measurements of outcomes were obtained through patient records (obtained through the Electronic Medical Record) and pharmacy data. A standardized chart review of the Electronic Medical Record was the primary source of data for both groups.

Secondary outcomes included appropriate osteoporosis management at 12 months and disease-specific quality of life measured using the OPTQoL \[[@B29]\], a quality of life questionnaire for people with osteoporosis.

Sample size and Analysis
------------------------

Local pilot data suggested that 40% of people would receive appropriate osteoporosis medications at 6 months. We determined a minimal clinically important difference of 20% and with a two-tailed alpha of 0.05, power of 0.80, the patient as the unit of allocation and analysis, and assuming a loss to follow-up of 10%, a total sample size of 200 patients was needed.

Relative risks with 95% confidence intervals were calculated to assess outcomes between the IP group and the usual care group at 6 months. Fisher\'s Exact Test was used to evaluate differences in outcomes between the IP group and the DP group at 12 months. Paired t-tests were used to detect differences in the OPTQoL at baseline and 6 months within each group. Analysis was by intention to treat.

Ethics approval was received from the Joint Group Health Centre/Sault Area Hospital Research and Ethics Board. This trial has been registered with <http://clinicaltrials.gov> (ID: NCT00465387)

Results
=======

Patient characteristics
-----------------------

590 patients were screened for eligibility, 389 were excluded and 201 patients were recruited from March 2003 to January 2006, with 101 patients randomized into the IP group, and 100 patients into the usual care group (Figure [1](#F1){ref-type="fig"}). One hundred seventy six patients (88%) completed the study. Mean age of participants was 71.9 ± 7.2 years and 94% were women. Most participants entered the study on the basis of a previous BMD test or referral from fracture clinic suggesting that the study population was at high risk of osteoporosis-related fracture. Baseline characteristics were similar among the groups (Table [1](#T1){ref-type="table"}). No statistically significant baseline differences were detected between groups with respect to presence of risk factors or differences in losses due to death and follow-up.

![**Flow of Trial Participants**.](1471-2318-10-60-1){#F1}

###### 

Baseline characteristics

  ------------------------------------------------------------------------
                                                 *N*= 201     
  ---------------------------------------------- ------------ ------------
  **Demographic, *n*(%)**                                     

   Mean age (years) ± SD                         72 ± 9.1     71 ± 7.7

   Female                                        92 (91.1%)   96 (96.0%)

   Male                                          9 (8.90%)    3 (3.00%)

   Aboriginal Origin                             2 (1.98%)    9 (9.00%)

  **Referral Source, *n*(%)**                                 

  \#1 SAH Fracture Clinic or BMD t-score ≤-2.0   74 (72.6%)   73 (73.0%)

  \#2 SAH Emergency Department                   4 (3.96%)    5 (5.00%)

  \#3 Self-referred or referred\                 23 (22.8%)   22 (22.0%)
  by health care provider\                                    
  and Timed Up and Go\                                        
  (TUG) \>14 s                                                

  **Osteoporosis Risk Factors, *n*(%)\***                     

   T-score +2.5 to -1.0                          10 (9.90%)   9 (9.00%)

   T-score -1.0 to -2.5                          39 (38.6%)   31 (31.0%)

   T-score ≤ -2.5                                52 (51.5%)   60 (60.0%)
  ------------------------------------------------------------------------

Note: All participants had a BMD completed as per protocol.

\*No significant differences were detected between groups

Primary Outcomes
----------------

### Osteoporosis risk management

For osteoporosis risk management (Table [2](#T2){ref-type="table"}), more than twice the number of patients with osteoporosis (BMD T-score ≤ -2.5) were taking alendronate, risedronate, or raloxifene in the IP group after 6 months compared to the usual care group (29/52 vs. 16/60; relative risk \[RR\] 2.09, 95% confidence interval (CI) 1.29 to 3.40). The difference in treatment rates was even greater for patients with low bone mass (T-score between -2.5 and -1.0) between the IP and usual care groups (16/39 vs. 5/31; RR 2.54, 95% CI 1.05 to 6.17). A higher proportion of patients in the IP group were using calcium (54/101 vs. 20/100; RR 2.67, 95% CI 1.74 to 4.12) and vitamin D (33/101 vs. 20/100; RR 1.63, 95% CI 1.01 to 2.65) at 6 months compared to the usual care group. There were more women in the IP group taking estrogen/progestin compared to the usual care group at 6 months (13/101 vs. 2/100; RR 6.77, 95% CI 1.49 to 27.8).

###### 

Management of osteoporosis risk from randomization date until 6 months after enrolment

                                                                                                 *N*= 201                                             
  ---------------------------------------------------------------------------------------------- ---------------- ---------------- ------------------ ----------------
  **Appropriate osteoporosis risk management**                                                                                                        
   Use of alendronate, risedronate, raloxifene with BMD result of t ≤ -2.5 (osteoporosis)        29/52 (55.8%)    16/60 (26.7%)    2.09 (1.29,3.40)   33/60 (55.0%)
   Use of alendronate, risedronate, raloxifene with BMD result of -2.5 \< t \< -1 (osteopenia)   16/39 (41.0%)    5/31 (16.1%)     2.54 (1.05,6.17)   8/31 (25.8%)
   Recommended amount of calcium                                                                 54/101 (53.5%)   20/100 (20.0%)   2.67 (1.74,4.12)   46/100 (46.0%)
   Recommended Amount of vitamin D                                                               33/101 (32.7%)   20/100 (20.0%)   1.63 (1.01,2.65)   36/100 (36.0%)
   Estrogen or progestin                                                                         13/101 (12.9%)   2/100 (2.00%)    6.44 (1.49,27.8)   6/100 (6.00%)
  **Health Status**                                                                                                                                   
   Mean OPTQoL score ± SD at baseline                                                            205 ± 58         212 ± 54         N/A                
   Mean OPTQoL score ± SD after 6 mos. of intervention                                           207 ± 55         220 ± 50                            
   P-value of difference                                                                         0.58             0.26                                

Note: IP = immediate intervention protocol; DP = delayed intervention protocol;

RR = relative rate; 95% CI = 95% confidence interval

\*No significant differences detected between IP and DP at 6-12 months for osteoporosis risk management variables

Secondary Outcomes
------------------

### Osteoporosis management

Following intervention in both groups at 12 months after randomization, the use of appropriate treatments for osteoporosis (alendronate, risedronate, raloxifene with BMD T-score ≤ -2.5) reached 56%. The usual care group improved to the same level of treatment with alendronate, risedronate, raloxifene, calcium, and vitamin D after receiving the intervention (*P =*0.48) (Table [2](#T2){ref-type="table"}).

### Quality of life and other patient-centered outcomes

Quality of life measured by the OPTQoL questionnaire remained similar within the IP group (*P*= 0.58) and DP group (*P =*0.26) over the course of the study (Table [2](#T2){ref-type="table"}). One participant in the IP group had a fragility fracture at 6 months compared with 6 participants in the usual care group (RR 0.17, 95% CI 0.02,1.35). Two individuals in the IP group were admitted to hospital with a fall-related injury compared with 3 in the usual care group (RR 0.66, 95% CI 0.11 to 3.87).

Discussion
==========

This study demonstrated that a multi-component intervention program directed at patients at risk for fracture and at their physicians doubled the rate of appropriate osteoporosis management compared to usual care in this community. The co-ordinated intervention increased rates of osteoporosis medication use by more than 20% over usual care, a consensus benchmark previously reported as what might be considered a clinically important benefit for such an intervention \[[@B30]\]. Our study increased pharmacological treatment of osteoporosis by 29% over local usual care (IP 56% vs. DP 27%). Similarly, a controlled trial by Majumdar et al reported appropriate use of osteoporosis medications to be 40% in the intervention group versus 10% in the usual care control, but only patients with a wrist fracture were eligible for inclusion \[[@B31]\]. A more recent trial of a case manager for patients with hip fracture found similar results to what was observed in our study \[[@B32]\]. With the improvements in care delivery observed in the current study, the appropriate osteoporosis treatments were utilized in over one-half of individuals with receipt of the intervention. This result is better than that achieved in most other studies of interventions to enhance implementation of osteoporosis management in broad populations of at-risk patients rather than restricted to patients with recent fracture. Randomized intervention studies directed at physicians and/or patients at high risk of osteoporosis-related fractures conducted by Solomon and colleagues \[[@B33],[@B34]\] and by Elston Lafata and colleagues \[[@B35]\] found that screening and treatment rates were either unaffected \[[@B33],[@B34]\] or improved by less than 10% \[[@B35]\]. And a recent study of a falls-and-fracture nurse coordinator found that neither falls nor osteoporosis management were enhanced with this intervention \[[@B36]\]. Thus, the present study achieved an effect size substantially larger than recent studies of similar design.

The strengths of this study included a randomized study design; an intervention targeted at high-risk patients; the successful partnership between numerous distinct community stakeholders; and that we were able to \'replicate\' the intervention\'s effects 6 months later in the DP group. Moreover, multiple health care providers and community health service groups collaborated in a coordinated assessment and treatment program to deliver evidence-based and timely interventions. Economic analysis of this study is currently underway.

The limitations of this study included: a short follow-up period of 6 months, which did not allow for longer-term results such as fracture data; and, no blinded outcomes assessors. The lack of blinding of the outcomes assessors could result in bias such as overestimation of the impact of the intervention. However, the primary source of data collection was the administrative data obtained from the Group Health Centre Electronic Medical Record. Even if we consider the lower limit of the confidence interval (for use of appropriate pharmacological therapy \[RR\] 2.09, 95% **CI 1.29**to 3.40) as the effect size, we consider this a clinically important change. Given that there is evidence that appropriate management of osteoporosis decreases fractures, it was felt that the use of appropriate management as the primary outcome was relevant. Indeed, when the evidence-base is well-established (such as in osteoporosis management), process-of-care measures are more sensitive to changes in quality of care than outcomes such as mortality or clinical events and are widely recognized as acceptable and appropriate endpoints for quality improvement studies.

Conclusions
===========

In summary, it is critical that the health care community address the deficiencies that exist with respect to knowledge translation and management of osteoporosis given the significant burden of disease related to fractures. This randomized, community-based study supports implementation of a co-ordinated osteoporosis management strategy for improved care in at-risk individuals, although long-term follow-up should be considered. Many of the assessment and treatment protocols used in this study could be employed in existing clinics and programs to enhance osteoporosis care in a community setting.
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Appendix: Risk Medications
==========================

Medications associated with an increased risk of [osteoporosis]{.ul}:

1\. *Glucocorticoids:*Cortef, cortisone, dexamethasone, hydrocortisone, prednisone, betamethasone, fludrocortisone, methylprednisone, prednisolone, tramcinolone.

2\. *Inhaled Corticosteroids:*beclomethasone, budesonide, fluticasone, flunisolide, tramcinolone.
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